Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the appointment of Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer effective November 21, 2022. Beaupre brings over 25 years of experience in clinical development, previously at Pfizer and BioSplice Therapeutics. His role will focus on expanding IDEAYA's clinical pipeline, aiming to include five clinical trials across four programs in 2023. IDEAYA specializes in synthetic lethality, targeting precision medicine oncology, with plans to leverage Beaupre's expertise to enhance its drug development efforts.

IDEAYA Biosciences (IDYA) reported a robust financial position with $393.9 million in cash and securities as of September 30, 2022, projected to support operations until 2026. The company disclosed positive Phase 2 interim clinical outcomes for darovasertib and crizotinib in metastatic uveal melanoma, targeting a potential registrational trial in Q1 2023. IDEAYA is advancing multiple clinical programs, including IDE397 and IDE161, and plans to initiate several trials in 2023. Collaboration revenue surged to $29.7 million, reflecting substantial milestones achieved in partnerships.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in key investor conferences throughout November 2022 and scheduled an Investor R&D Day for December 12, 2022. The Jefferies London Healthcare Conference will feature a fireside chat with CEO Yujiro Hata on November 15, while the Stifel Healthcare Conference will include CFO Paul Stone on November 16. The R&D Day aims to showcase insights from IDEAYA's clinical and preclinical programs, with a live webcast available for participants. For details, visit IDEAYA's investor relations page.

IDEAYA Biosciences (NASDAQ: IDYA) has announced the dosing of the first patient in two combination therapy cohorts involving IDE397, a MAT2A inhibitor, in patients with MTAP-deletion tumors. This includes combinations with pemetrexed and taxanes, presenting a potential first-in-class option. The Phase 1/2 trial, which aims to evaluate clinical efficacy, builds on positive preclinical data demonstrating robust tumor target engagement. Additionally, IDEAYA plans to assess IDE397 in collaboration with AMG 193, targeting dual signaling pathways in these tumors.

IDEAYA Biosciences (NASDAQ:IDYA) announced the closure of its public offering of 8,761,905 shares of common stock at $10.50 per share, raising approximately $92 million before underwriting costs. This includes the complete exercise of the underwriters' option for an additional 1,142,857 shares. J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities led the offering, conducted under an SEC-approved shelf registration statement. IDEAYA focuses on precision medicine in oncology, utilizing synthetic lethality in its therapeutic development.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced a public offering of 7,619,048 shares of its common stock priced at $10.50 per share, aiming to raise approximately $80.0 million before expenses. The offering includes an option for underwriters to purchase up to an additional 1,142,857 shares. The gross proceeds could increase if the option is exercised. The transaction is expected to close on or around September 19, 2022. Key underwriters include J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities.

IDEAYA Biosciences (Nasdaq:IDYA) announced its intention to offer and sell up to $80.0 million in common stock through an underwritten public offering, with a potential additional $12.0 million from over-allotment options. The offering is contingent on market conditions and other factors, with no guaranteed completion date or terms. The underwriters include major banks like J.P. Morgan and Jefferies. This offering is made under a previously filed shelf registration statement with the SEC, and related prospectus information will be available through the underwriters.

IDEAYA Biosciences (IDYA) announced interim results from its Phase 2 clinical trial of darovasertib and crizotinib in metastatic uveal melanoma (MUM). The trial showed a **50% overall response rate** (ORR) in first-line MUM patients and an **89% tumor shrinkage** rate in any-line MUM patients. The observed median progression-free survival (PFS) was over **5 months** in first-line MUM patients. No FDA-approved therapies exist for GNAQ and GNA11 solid tumors, indicating a high unmet medical need. IDEAYA plans to initiate a registration-enabling trial in Q1 2023.

IDEAYA Biosciences has initiated an Investigator Sponsored Trial (IST) in Australia to evaluate darovasertib as a monotherapy for primary, non-metastatic uveal melanoma (UM). Preliminary signs of clinical activity show tumor shrinkage in patients following treatment. With an annual incidence of about 8,700 patients in the US and EU, (neo)adjuvant UM represents an unmet medical need. The trial aims to assess the feasibility and tolerability of darovasertib, following anecdotal evidence of effectiveness. Clinical proof-of-concept data is expected in September 2022.